Cat. #151025
Anti-Vascular endothelium [10]
Cat. #: 151025
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Vascular endothelium marker
Class: Monoclonal
Application: IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Nancy Hogg
Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Vascular endothelium [10]
- Research fields: Cancer;Cell biology;Tissue-specific biology
- Clone: 10
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: IHC
- Description: Monoclonal antibody which specifically binds vascular endothelium tissue.
- Immunogen: Fibronectin-purified human monocytes.
- Isotype: IgM
- Myeloma used: Sp2/0-Ag14
Target Details
- Target: Vascular endothelium marker
- Target background: The vascular endothelium comprises the thin inner layer of cells lining arteries and veins, with an essential role in the regulation of blood vessel tone and cellular activity. This antibody may be used to study the synovial membrane in rheumatoid, osteoarthritic and traumatised joints as well as normal vasculature. Anti-vascular endothelium (10) reactivity is stronger on capillary endothelium and weaker on larger arteries and veins.
Applications
- Application: IHC
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
- Shipping conditions: Shipping at 4° C
References
- Palmer et al. 1985. Clin Exp Immunol. 59(3):529-38. PMID: 3886218.
- Features of synovial membrane identified with monoclonal antibodies.
